earnings
confidence high
sentiment negative
materiality 0.65
Kodiak Sciences Q1 net loss $95.7M ($1.83/share); updates KSI-301 program after Ph2b/3 miss
Kodiak Sciences Inc.
2023-Q1 EPS reported
-$1.83
- Net loss $95.7M ($1.83/share) vs $50.4M ($0.98/share) in Q1 2021.
- R&D expenses $76.2M, up 89% YoY; G&A $19.6M, up 92% YoY; cash $671.7M.
- KSI-301 Phase 2b/3 wet AMD missed primary endpoint; ongoing Phase 3 studies modified to reduce undertreatment risk.
- BEACON top-line data expected August 2022; DAYLIGHT, GLEAM, GLIMMER data mid-2023.
- Commercial manufacturing facility in Visp, Switzerland reached mechanical completion March 2022.